Clinical Trial Detail

NCT ID NCT02665065
Title Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory AML (SIERRA)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Actinium Pharmaceuticals
Indications

acute myeloid leukemia

Therapies

Fludarabine + Iomab-B

Age Groups: adult senior

No variant requirements are available.